Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 32


Evaluation of drug mechanism and efficacy of a novel anti-angiogenic agent, TTAC-0001, using multi-modality bioimaging in a mouse breast cancer orthotopic model.

Kim J, Choi SH, Ham SJ, Cho YC, Lee SI, Kang J, Woo DC, Lee WS, Yoo JS, Kim KW, Choi Y.

PLoS One. 2018 Jan 25;13(1):e0187063. doi: 10.1371/journal.pone.0187063. eCollection 2018.


Myc Cooperates with Ras by Programming Inflammation and Immune Suppression.

Kortlever RM, Sodir NM, Wilson CH, Burkhart DL, Pellegrinet L, Brown Swigart L, Littlewood TD, Evan GI.

Cell. 2017 Nov 30;171(6):1301-1315.e14. doi: 10.1016/j.cell.2017.11.013.


Platelets and cancer angiogenesis nexus.

Wojtukiewicz MZ, Sierko E, Hempel D, Tucker SC, Honn KV.

Cancer Metastasis Rev. 2017 Jun;36(2):249-262. doi: 10.1007/s10555-017-9673-1.


Anticancer activity of TTAC-0001, a fully human anti-vascular endothelial growth factor receptor 2 (VEGFR-2/KDR) monoclonal antibody, is associated with inhibition of tumor angiogenesis.

Kim DG, Jin Y, Jin J, Yang H, Joo KM, Lee WS, Shim SR, Kim SW, Yoo J, Lee SH, Yoo JS, Nam DH.

MAbs. 2015;7(6):1195-204. doi: 10.1080/19420862.2015.1086854. Epub 2015 Sep 1.


Systemic and Cerebral Vascular Endothelial Growth Factor Levels Increase in Murine Cerebral Malaria along with Increased Calpain and Caspase Activity and Can be Reduced by Erythropoietin Treatment.

Hempel C, Hoyer N, Kildemoes A, Jendresen CB, Kurtzhals JA.

Front Immunol. 2014 Jun 19;5:291. doi: 10.3389/fimmu.2014.00291. eCollection 2014.


Tumor VEGF:VEGFR2 autocrine feed-forward loop triggers angiogenesis in lung cancer.

Chatterjee S, Heukamp LC, Siobal M, Schöttle J, Wieczorek C, Peifer M, Frasca D, Koker M, König K, Meder L, Rauh D, Buettner R, Wolf J, Brekken RA, Neumaier B, Christofori G, Thomas RK, Ullrich RT.

J Clin Invest. 2013 Apr;123(4):1732-40. Erratum in: J Clin Invest. 2013 Jul 1;123(7):3183.


Vascular density analysis in colorectal cancer patients treated with vatalanib (PTK787/ZK222584) in the randomised CONFIRM trials.

Giatromanolaki A, Koukourakis MI, Sivridis E, Gatter KC, Trarbach T, Folprecht G, Shi MM, Lebwohl D, Jalava T, Laurent D, Meinhardt G, Harris AL; Tumour and Angiogenesis Research Group.

Br J Cancer. 2012 Sep 25;107(7):1044-50. doi: 10.1038/bjc.2012.369. Epub 2012 Aug 21.


Endogenous Myc maintains the tumor microenvironment.

Sodir NM, Swigart LB, Karnezis AN, Hanahan D, Evan GI, Soucek L.

Genes Dev. 2011 May 1;25(9):907-16. doi: 10.1101/gad.2038411. Epub 2011 Apr 8.


r84, a novel therapeutic antibody against mouse and human VEGF with potent anti-tumor activity and limited toxicity induction.

Sullivan LA, Carbon JG, Roland CL, Toombs JE, Nyquist-Andersen M, Kavlie A, Schlunegger K, Richardson JA, Brekken RA.

PLoS One. 2010 Aug 6;5(8):e12031. doi: 10.1371/journal.pone.0012031.


HSPG-binding peptide corresponding to the exon 6a-encoded domain of VEGF inhibits tumor growth by blocking angiogenesis in murine model.

Lee TY, Folkman J, Javaherian K.

PLoS One. 2010 Apr 1;5(4):e9945. doi: 10.1371/journal.pone.0009945.


The VEGF family in cancer and antibody-based strategies for their inhibition.

Sullivan LA, Brekken RA.

MAbs. 2010 Mar-Apr;2(2):165-75. Review.


Lack of host SPARC enhances vascular function and tumor spread in an orthotopic murine model of pancreatic carcinoma.

Arnold SA, Rivera LB, Miller AF, Carbon JG, Dineen SP, Xie Y, Castrillon DH, Sage EH, Puolakkainen P, Bradshaw AD, Brekken RA.

Dis Model Mech. 2010 Jan-Feb;3(1-2):57-72. doi: 10.1242/dmm.003228. Epub 2009 Dec 9.


The Adnectin CT-322 is a novel VEGF receptor 2 inhibitor that decreases tumor burden in an orthotopic mouse model of pancreatic cancer.

Dineen SP, Sullivan LA, Beck AW, Miller AF, Carbon JG, Mamluk R, Wong H, Brekken RA.

BMC Cancer. 2008 Nov 27;8:352. doi: 10.1186/1471-2407-8-352.


VEGF neutralizing antibody increases the therapeutic efficacy of vinorelbine for renal cell carcinoma.

Sinha S, Cao Y, Dutta S, Wang E, Mukhopadhyay D.

J Cell Mol Med. 2010 Mar;14(3):647-58. doi: 10.1111/j.1582-4934.2008.00578.x. Epub 2008 Nov 7.


Effect of ablation or inhibition of stromal matrix metalloproteinase-9 on lung metastasis in a breast cancer model is dependent on genetic background.

Martin MD, Carter KJ, Jean-Philippe SR, Chang M, Mobashery S, Thiolloy S, Lynch CC, Matrisian LM, Fingleton B.

Cancer Res. 2008 Aug 1;68(15):6251-9. doi: 10.1158/0008-5472.CAN-08-0537.


Matrix metalloproteinase-2 regulates vascular patterning and growth affecting tumor cell survival and invasion in GBM.

Du R, Petritsch C, Lu K, Liu P, Haller A, Ganss R, Song H, Vandenberg S, Bergers G.

Neuro Oncol. 2008 Jun;10(3):254-64. doi: 10.1215/15228517-2008-001. Epub 2008 Mar 21.


Genetic alteration of endothelial heparan sulfate selectively inhibits tumor angiogenesis.

Fuster MM, Wang L, Castagnola J, Sikora L, Reddi K, Lee PH, Radek KA, Schuksz M, Bishop JR, Gallo RL, Sriramarao P, Esko JD.

J Cell Biol. 2007 May 7;177(3):539-49. Epub 2007 Apr 30.


In vivo models of angiogenesis.

Norrby K.

J Cell Mol Med. 2006 Jul-Sep;10(3):588-612. Review.


Loss of SPARC-mediated VEGFR-1 suppression after injury reveals a novel antiangiogenic activity of VEGF-A.

Nozaki M, Sakurai E, Raisler BJ, Baffi JZ, Witta J, Ogura Y, Brekken RA, Sage EH, Ambati BK, Ambati J.

J Clin Invest. 2006 Feb;116(2):422-9.


Phase I trial of intravesical Suramin in recurrent superficial transitional cell bladder carcinoma.

Ord JJ, Streeter E, Jones A, Le Monnier K, Cranston D, Crew J, Joel SP, Rogers MA, Banks RE, Roberts IS, Harris AL.

Br J Cancer. 2005 Jun 20;92(12):2140-7.

Supplemental Content

Support Center